恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002262 恩华药业

已收盘 07-03 15:00:00

{"stockData":{"symbol":"002262","market":"SZ","secType":"STK","nameCN":"恩华药业","latestPrice":23.55,"timestamp":1719990195000,"preClose":23.71,"halted":0,"volume":5291353,"delay":0,"floatShares":882000000,"shares":1008000000,"eps":1.0667,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.16,"latestTime":"07-03 15:00:00","open":23.55,"high":23.69,"low":23.26,"amount":124000000,"amplitude":0.0181,"askPrice":23.56,"askSize":42,"bidPrice":23.55,"bidSize":863,"shortable":0,"etf":0,"ttmEps":1.0667,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"adjPreClose":23.71,"symbolType":"stock","openAndCloseTimeList":[[1719970200000,1719977400000],[1719982800000,1719990000000]],"highLimit":26.08,"lowLimit":21.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1007588092,"pbRate":3.57,"roa":"--","roe":"4.04%","epsLYR":1.03,"committee":0.034903,"marketValue":23729000000,"floatMarketCap":20765000000,"peRate":22.077435,"changeRate":-0.0067,"turnoverRate":0.006,"status":1},"requestUrl":"/m/hq/s/002262","defaultTab":"news","newsList":[{"id":"2445706108","title":"恩华药业公布国际专利申请：“一种取代四氢环戊基[c]吡咯衍生物、制备方法、中间体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2445706108","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445706108?lang=zh_cn&edition=full","pubTime":"2024-06-23 04:40","pubTimestamp":1719088837,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示恩华药业公布了一项国际专利申请，专利名为“一种取代四氢环戊基[c]吡咯衍生物、制备方法、中间体及其应用”，专利申请号为PCT/CN2023/137347，国际公布日为2024年6月20日。专利详情如下：图片来源：世界知识产权组织今年以来恩华药业已公布的国际专利申请7个，较去年同期增加了75%。结合公司2023年年报财务数据，2023年公司在研发方面投入了5.49亿元，同比增20.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062300001124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","002262","BK0188"],"gpt_icon":0},{"id":"2444844007","title":"恩华药业最新公告：获得普瑞巴林胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2444844007","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444844007?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:30","pubTimestamp":1718785853,"startTime":"0","endTime":"0","summary":"恩华药业公告，公司于近日获得国家药品监督管理局核准签发的化学药品普瑞巴林胶囊的《药品注册证书》。普瑞巴林胶囊用于治疗带状疱疹后神经痛和纤维肌痛。本次获得普瑞巴林胶囊的《药品注册证书》，丰富了公司在中枢神经领域的产品管线，有利于提升公司的市场竞争力，其上市销售将对公司今后业绩的提升产生积极的影响。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900032820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0070","BK0188","BK0239"],"gpt_icon":0},{"id":"2444244011","title":"恩华药业(002262.SZ)：盐酸戊乙奎醚注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2444244011","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444244011?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:30","pubTimestamp":1718785823,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于盐酸戊乙奎醚注射液(1ml:0.5mg规格)的《药品补充申请批准通知书》，批准该规格药品通过仿制药质量和疗效一致性评价。公告显示，盐酸戊乙奎醚注射液为选择性抗胆碱药。用于麻醉前给药以抑制唾液腺和气道腺体分泌。用于有机磷毒物(农药)中毒急救治疗和中毒后期或胆碱酯酶(ChE)老化后维持阿托品化。公司在该产品的一致性评价项目上已投入研发费用约89万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1137329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","BK0188","002262"],"gpt_icon":0},{"id":"2444325440","title":"恩华药业(002262.SZ)：普瑞巴林胶囊获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2444325440","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444325440?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:22","pubTimestamp":1718785321,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)公告，公司近日获得国家药品监督管理局核准签发的化学药品普瑞巴林胶囊的《药品注册证书》。普瑞巴林胶囊用于治疗带状疱疹后神经痛和纤维肌痛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1137325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","002262","BK0188"],"gpt_icon":0},{"id":"2443990841","title":"恩华药业公布国际专利申请：“并环类衍生物、其制备方法、中间体和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2443990841","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443990841?lang=zh_cn&edition=full","pubTime":"2024-06-16 04:33","pubTimestamp":1718483594,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示恩华药业公布了一项国际专利申请，专利名为“并环类衍生物、其制备方法、中间体和应用”，专利申请号为PCT/CN2023/137329，国际公布日为2024年6月13日。专利详情如下：图片来源：世界知识产权组织今年以来恩华药业已公布的国际专利申请6个，较去年同期增加了50%。结合公司2023年年报财务数据，2023年公司在研发方面投入了5.49亿元，同比增20.93%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061600000284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002262","BK0070","BK0188"],"gpt_icon":0},{"id":"2442553075","title":"恩华药业最新公告：拟推876.16万股的2024年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2442553075","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442553075?lang=zh_cn&edition=full","pubTime":"2024-06-12 20:17","pubTimestamp":1718194631,"startTime":"0","endTime":"0","summary":"恩华药业公布2024年限制性股票激励计划(草案)，本次激励计划拟向激励对象授予的限制性股票数量为876.16万股，约占本次激励计划草案公告时公司股本总额100,758.81万股的0.8696%。本次激励计划限制性股票的授予价格为11.51元/股。本次激励计划激励对象总人数为860人。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061200039229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","002262","BK0239"],"gpt_icon":0},{"id":"2442534750","title":"恩华药业(002262.SZ)拟推2024年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2442534750","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442534750?lang=zh_cn&edition=full","pubTime":"2024-06-12 19:01","pubTimestamp":1718190063,"startTime":"0","endTime":"0","summary":"恩华药业(002262.SZ)发布2024年限制性股票激励计划(草案)，拟向激励对...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/10.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/10.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0070","BK0239","BK0188","002262"],"gpt_icon":0},{"id":"2442363964","title":"恩华药业：公司碳酸锂缓释片在2023年销售额为1.04亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442363964","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442363964?lang=zh_cn&edition=full","pubTime":"2024-06-11 18:06","pubTimestamp":1718100367,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月11日在投资者关系平台上答复投资者关心的问题。投资者：请问公司碳酸锂缓释片在2023年销售额为多少？市场地位如何？恩华药业董秘：公司碳酸锂缓释片在2023年销售额为1.04亿元。该产品为公司独家销售。谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100023851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","002262"],"gpt_icon":0},{"id":"2440472452","title":"恩华药业新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2440472452","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440472452?lang=zh_cn&edition=full","pubTime":"2024-06-04 14:39","pubTimestamp":1717483188,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日江苏恩华药业股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来江苏恩华药业股份有限公司新申请注册商标3件，截止目前公司共持有注册商标706件，另有32件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060400022684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","002262","BK0239"],"gpt_icon":0},{"id":"2437810967","title":"恩华药业最新公告：获得拉考沙胺注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437810967","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437810967?lang=zh_cn&edition=full","pubTime":"2024-05-23 16:26","pubTimestamp":1716452780,"startTime":"0","endTime":"0","summary":"恩华药业公告，公司于近日获得国家药品监督管理局核准签发的化学药品拉考沙胺注射液的《药品注册证书》。拉考沙胺注射液适用于4岁及以上癫痫患者部分性发作的联合治疗。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300029261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","002262","BK0188"],"gpt_icon":0},{"id":"2437717785","title":"恩华药业(002262.SZ)取得拉考沙胺注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437717785","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437717785?lang=zh_cn&edition=full","pubTime":"2024-05-23 15:53","pubTimestamp":1716450790,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)公告，公司近日获得国家药品监督管理局核准签发的化学药品拉考沙胺注射液的《药品注册证书》，拉考沙胺注射液适用于4岁及以上癫痫患者部分性发作的联合治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1125059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","BK0188","002262"],"gpt_icon":0},{"id":"2434641130","title":"恩华药业：碳酸锂价格降低有利于公司碳酸锂缓释片产品成本的控制","url":"https://stock-news.laohu8.com/highlight/detail?id=2434641130","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434641130?lang=zh_cn&edition=full","pubTime":"2024-05-09 18:04","pubTimestamp":1715249059,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业05月09日在投资者关系平台上答复投资者关心的问题。投资者：2023年碳酸锂价格走低，请问对贵司碳酸锂缓释片这个产品有何影响？此外为何网上买不到碳酸锂缓释片？公司碳酸锂缓释片为处方药，需凭医师或其他有处方权的医疗专业人员开具处方出售，并在医师、药师或其他医疗专业人员监督或指导下使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900032922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","002262","BK0239"],"gpt_icon":0},{"id":"2433225746","title":"恩华药业(002262.SZ)2023年年度权益分派：每10股派3.20元 5月14日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2433225746","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433225746?lang=zh_cn&edition=full","pubTime":"2024-05-07 16:52","pubTimestamp":1715071979,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)发布2023年年度权益分派实施公告，以公司现有总股本为基数，向全体股东每10股派3.20元人民币现金。本次权益分派股权登记日为：2024年5月14日，除权除息日为：2024年5月15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1118204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0070","BK0239","002262"],"gpt_icon":0},{"id":"2432131714","title":"恩华药业公布国际专利申请：“一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2432131714","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432131714?lang=zh_cn&edition=full","pubTime":"2024-05-04 04:31","pubTimestamp":1714768261,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示恩华药业公布了一项国际专利申请，专利名为“一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用”，专利申请号为PCT/CN2023/126353，国际公布日为2024年5月2日。专利详情如下：图片来源：世界知识产权组织今年以来恩华药业已公布的国际专利申请4个，与去年同期持平。结合公司2023年年报财务数据，2023年公司在研发方面投入了5.49亿元，同比增20.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050400003329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","002262"],"gpt_icon":0},{"id":"2423466821","title":"恩华药业(002262.SZ)发布2023年度业绩，净利润10.37亿元，增长15.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2423466821","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2423466821?lang=zh_cn&edition=full","pubTime":"2024-03-29 20:22","pubTimestamp":1711714920,"startTime":"0","endTime":"0","summary":"恩华药业发布2023年年度报告，报告期内，公司实现营业收入50.42亿元，同比增长17.28%。实现归属于上市公司股东的扣除非经常性损益的净利润10.13亿元，同比增长16.11%。基本每股收益为1.03元。拟向全体股东每10股派发现金红利3.20元(含税)。报告期内，公司主要的业绩驱动因素体现在以下方面：1、根据临床学术理念的发展及需求痛点的不断变化，与时俱进，适时调整重点产品品牌策略满足临床需求，建立产品的差异化竞争优势，实现老产品的稳定增长。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapyyan4386482.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapyyan4386482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002262"],"gpt_icon":0},{"id":"2414839507","title":"梯瓦制药(TEVA)涨近3% 与恩华药业达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2414839507","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414839507?lang=zh_cn&edition=full","pubTime":"2024-02-26 23:47","pubTimestamp":1708962464,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药(TEVA)早盘反复扬升，截止发稿，涨2.8%。 梯瓦日前与恩华药业在恩华科技大厦举行梯瓦与恩华战略合作暨安泰坦中国共同商业化合作签约仪式。此次合作标志着双方在精神神经领域的合作迈出了重要的一步。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"273408","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4585","BK0188","BK4557","BK4588","TEVA","BK0239","BK4566","BK4007","BK0070","002262","BK4559"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2008-07-23","address":"江苏省徐州市鼓楼区经济技术开发区杨山路18号","stockEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0526},{"period":"6month","weight":-0.1418},{"period":"1year","weight":-0.199},{"period":"ytd","weight":-0.1143}],"companyName":"江苏恩华药业股份有限公司","boardCode":"AI0027","perCapita":"35803股","boardName":"医药制造业","registeredCapital":"100758万元","compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.0291},{"period":"3month","weight":-0.0236},{"period":"6month","weight":0.0144},{"period":"1year","weight":-0.0761},{"period":"ytd","weight":0.0074}],"survey":"　　江苏恩华药业股份有限公司主营业务为医药生产、研发和销售，医药销售含公司生产的制剂销售及医药批发和零售业务。公司主要从事中枢神经类药物及心脑血管类药物的研发。公司是国家定点麻醉及精神药品生产基地，是国内重要的中枢神经系统药物的生产商和销售商，同时也是国内唯一一家专注于中枢神经系统药物研发和生产的制药企业。","serverTime":1720023245140,"listedPrice":5.68,"stockholders":"24628人(较上一季度增加22.79%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩华药业,002262,恩华药业股票,恩华药业股票老虎,恩华药业股票老虎国际,恩华药业行情,恩华药业股票行情,恩华药业股价,恩华药业股市,恩华药业股票价格,恩华药业股票交易,恩华药业股票购买,恩华药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}